For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development (including 10,125,000 for the year ended december 31, 2025 and 2,801,435 for the six months ended december 31, 2024, from a related party) | 10,248,545 | |||
| General and administrative | 2,814,129 | |||
| Total operating expenses | 13,062,674 | |||
| Loss from operations | -13,062,674 | |||
| Loss before income taxes | -13,062,674 | |||
| Income tax provision | 838 | |||
| Net loss | -13,063,512 | |||
| Basic EPS | -0.35 | |||
| Diluted EPS | -0.35 | |||
| Basic Average Shares | 36,820,810 | |||
| Diluted Average Shares | 36,820,810 | |||
Estrella Immunopharma, Inc. (ESLAW)
Estrella Immunopharma, Inc. (ESLAW)